uniQure (UQ1.F) shares fall 38% after updated Huntington’s disease gene therapy data
uniQure’s US-listed shares drop 38% to $24.25, the lowest level in over four months, after updated 36- and 48-month data for its Huntington’s disease gene therapy.
(Updates) * US-listed shares of gene therapy developer uniQure fall 38% to $24.25 * Stock hits lowest level in over four months * Co says its experimental gene therapy for Huntington's disease, an inherited brain disorder, continued to slow disease progression in an early- to mid-stage study * Updated 36-month data showed 80% slowing of disease progression on cUHDRS, a measure of Huntington's disease progression, and 67% on Total Functional Capacity, the main measure in its confirmatory study * At 48 months, cUHDRS, the primary endpoint, showed 44% slowing but missed statistical significance; Total Functional Capacity showed 61% slowing * FDA previously accepted 36-month data as the basis for the company's accelerated approval application * Including sessions move, stock up ~1 YTD (Reporting by Sahil Pandey in Bengaluru) ((mailto:Sahil.Pandey@thomsonreuters.com)